South Korea’s bio industry is increasingly shifting the center of its growth strategy toward clinical-stage development, judging that transferring candidate compounds too early limits value recovery. Domestic clinical research R&D investment has already grown to 1.0922 trillion won, but with only a 7.9% chance that a drug candidate entering Phase 1 will ultimately receive final approval, securing funding and institutional support through later stages has become a key challenge. As a result, companies are also moving away from reliance on a single successful product and accelerating structures that advance multiple pipelines into clinical trials. Plans for up to three next-generation drug candidates to enter Phase 1 next year and the first patient dosing in the global Phase 1b/2 trial 'JET' show that Korean biotech firms are moving beyond simple discovery into full-scale development, including combination strategies and indication expansion.

In Japan, sleep is increasingly being treated not simply as rest, but as a life skill that should be measured and improved. With more than 45,000 applications submitted for an urban event and the country’s average daily sleep time recorded at a relatively short 7 hours and 22 minutes, sleep deprivation is increasingly being recognized as both an everyday discomfort and a management issue. This trend is reshaping consumer culture toward reclaiming sleep that had been cut back amid busy lifestyles. Rather than following a supposedly correct number of sleep hours, people are trying to find the level of recovery that suits them personally, while companies are expanding the market by turning that anxiety into products and services.

Natural products have long been discussed as promising materials, but at the commercialization stage they have often been pushed aside because of development difficulty and weak reward structures. In South Korea in particular, their presence has diminished to the point that only 27 of 2,162 domestic drug development pipeline cases involve natural-product drugs, while in the United States there is a renewed push to rebuild the investment environment through regulatory improvements and incentives such as 12 years of market exclusivity. This gap highlights not so much differences in research capability as the question of how the pathway from research to products and clinical use is designed. In Korea as well, exchange platforms such as the Gangneung Natural Products Bio International Conference are expanding, and concrete results targeting specific diseases, such as studies on ursolic acid and cancer cachexia, are emerging, making institutional and investment structures that can absorb development risk a more important competitive factor than simply accumulating papers.

Food authorities are expanding flexibility in product design by abolishing the upper limit on daily probiotic intake, while at the same time tightening safety measures by restricting the mixing of ingredients that carry liver-disease-related intake warnings. This is seen as an effort to reduce risks arising from combined consumption and excessive expectations without stifling industry innovation. In the same context, products that meet low-sugar standards by using sweeteners will be restricted from using labels that imply blood sugar management benefits. This is a significant move to correct the problem of consumers being misled when messages about low sugar, functionality, and health management are mixed together in a single product.

The field of Korean medicine has now moved beyond preserving traditional knowledge and has entered a full-scale phase of reorganizing clinical and literature data into machine-readable formats. Research institutions are prioritizing the establishment of an AI Korean Medicine Hub and the improvement of data governance, but the lack of sufficient AI and digital budgets for Korean medicine is putting both speed and sustainability to the test. This trend also aligns with changes in the research environment. As the PBS system is being phased out this year, there is more room to reduce the burden of securing short-term projects and focus on building long-term infrastructure. At the same time, how steadily the field can secure AI talent and continue standardization work will be a key factor determining its competitiveness.

Domestic new drug development and global pharmaceutical investment in Korea continue to grow, with global drugmakers operating in Korea recording a total of KRW 1.0922 trillion in R&D investment related to local clinical research last year. However, on the ground where development speed is determined, 53% of Phase 2 and 3 clinical trials are being delayed, revealing a structure in which rising patient recruitment difficulties, institutional burden, and procedural complexity prevent greater investment from translating directly into stronger competitiveness. In this environment, even companies with promising candidates face heavier financial pressure. Cases such as Voronoi, which is conducting clinical trials across 29 sites in 10 countries, show that even with strong early results, prolonged in-house development increases both costs and operational burden, making more precise judgment on clinical design and the timing of technology transfer increasingly important.

Rather than dismissing fatigue and lethargy as simple aging or a temporary dip in condition, there is a growing trend toward interpreting the body’s signals more specifically. Different causes—such as low testosterone, sleep disorders, and impaired kidney function—can produce similar fatigue, and the fact that testosterone declines by about 1 percent annually after one’s 30s has been highlighted alongside guidance that persistent symptoms warrant evaluation by a urologist or endocrinologist. This shift shows that health information is moving beyond merely describing symptoms toward differential assessment and early response. As it becomes more important to distinguish between fatigue that can be resolved through lifestyle changes and fatigue that requires evaluation for chronic disease, everyday discomfort is increasingly being treated as the starting point for medical judgment.

The focus of agricultural technology is shifting from simply accumulating research achievements to directly reducing labor in the field. Gochang has introduced 18 AI autonomous tractors to respond to aging and labor shortages, while the Rural Development Administration has laid the groundwork for faster access to information needed for research and farming decisions through a large language model specialized in agricultural life sciences. This shift reflects the fact that agriculture can no longer rely on cheap labor. As mechanized automation and the digitalization of specialized knowledge advance together, they will go beyond improving productivity to create a new operating system that supports the sustainability of regional agriculture.

Food authorities have decided to narrow the scope of labeling for general foods rather than expand expressions that enhance their health image, in order to prevent consumers from confusing the nature of products. In particular, under standards that will take effect on January 1, 2028, products using sweeteners will not be allowed to display related functionality claims for blood sugar management... This change is not simply a cleanup of wording, but the result of years of concern over consumer misunderstanding leading to institutional reform. Authorities appear intent on blocking the possibility that general foods could be perceived as tools for disease management, meaning that even as the market for functionally labeled foods grows, the responsibility attached to such expressions has become heavier...